Investigating the role of IL-33 in postoperative cognitive dysfunction after major abdominal surgery
Perioperative IL-33 is Associated with the Early Stage of Postoperative Neurocognitive Dysfunction After Major Abdominal Surgery
This study is trying to see if the inflammatory protein IL-33 is linked to memory and thinking problems after major abdominal surgery in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Sex | All |
| Sponsor | First Affiliated Hospital of Kunming Medical University Academic / other |
| Locations | 1 site (Kunming, Yunnan) |
| Trial ID | NCT06704451 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the association between the inflammatory protein IL-33 and the occurrence of postoperative neurocognitive dysfunction (PND) in patients undergoing major abdominal surgery. A total of 150 patients will be enrolled, and their neurocognitive functions will be assessed using a series of standardized questionnaires one day before and three days after surgery. Blood samples will be collected to measure IL-33 levels, allowing researchers to evaluate its potential as a biomarker for early-stage PND. The study seeks to clarify the relationship between IL-33 and cognitive outcomes in the context of gastrointestinal and hepatic surgeries.
Who should consider this trial
Good fit: Ideal candidates include patients with an American Society of Anesthesiologists status of II to IV who are scheduled for gastrointestinal or hepatic surgery.
Not a fit: Patients with a history of mental diseases, current neurological conditions, or severe preoperative cognitive dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could identify IL-33 as a biomarker for early detection of postoperative cognitive dysfunction, potentially leading to improved patient management and outcomes.
How similar studies have performed: While the relationship between IL-33 and postoperative cognitive dysfunction is not well-established, similar studies exploring biomarkers for cognitive outcomes have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:Patients were included if they had an American Society of Anesthesiologists status of Ⅱto Ⅳ and requiring a Gastrointestinal or a Hepatic surgery . Exclusion Criteria: 1. history of mental diseases; 2. patients with current Neurological disease; 3. patients who refused or were unable to finish the neurocognitive evaluation; 4. preoperative Mini-Mental Stare Examination (MMSE) less than required score (illiteracy \<17; primary school \< 20; middle school and higher \< 24).
Where this trial is running
Kunming, Yunnan
- The first affiliated hospital of KUNMING medical university — Kunming, Yunnan, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.